TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07205718: An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent i

Sponsor: Takeda · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 273 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$11,898,810

Rescue Site Savings

+$7,854,000

Unlock Full NCT07205718 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07205718 Rescue Dossier →